RHONDA LYNETTE HELLUMS - 02 Jan 2026 Form 4 Insider Report for Silence Therapeutics plc (SLN)

Role: Chief Financial Officer, Director
Signature: /s/ Rhonda Hellums
Issuer symbol: SLN
Transactions as of: 02 Jan 2026
Net transactions value: $0
Form type: 4
Filing time: 06 Jan 2026, 16:15:09 UTC
Previous filing: 02 Jan 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
HELLUMS RHONDA LYNETTE	Chief Financial Officer, Director	C/O SILENCE THERAPEUTICS PLC, 12 HAMMERSMITH GROVE, LONDON, UNITED KINGDOM	/s/ Rhonda Hellums	06 Jan 2026	0001766456

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SLN	Employee Share Option (Right to Buy)	Award	$0	+375,000		$0.000000	375,000	02 Jan 2026	Ordinary Shares	375,000	$2.05	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	One fourth (1/4th) of the shares subject to the option shall vest on January 2, 2027 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer on each such vesting date.